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Abstract: Nutrigenetic studies analyzing gene–diet interactions of the TCF7L2-rs7903146 C > T
polymorphism on type-2 diabetes (T2D) have shown controversial results. A reason contributing
to this may be the additional modulation by obesity. Moreover, TCF7L2-rs7903146 is one of the
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most influential variants in T2D-genetic risk scores (GRS). Therefore, to increase the predictive value
(PV) of GRS it is necessary to first see whether the included polymorphisms have heterogeneous
effects. We comprehensively investigated gene-obesity interactions between the TCF7L2-rs7903146
C > T polymorphism on T2D (prevalence and incidence) and analyzed other T2D-polymorphisms
in a sub-sample. We studied 7018 PREDIMED participants at baseline and longitudinally (8.7 years
maximum follow-up). Obesity significantly interacted with the TCF7L2-rs7903146 on T2D prevalence,
associations being greater in non-obese subjects. Accordingly, we prospectively observed in non-T2D
subjects (n = 3607) that its association with T2D incidence was stronger in non-obese (HR: 1.81; 95%
CI: 1.13–2.92, p = 0.013 for TT versus CC) than in obese subjects (HR: 1.01; 95% CI: 0.61–1.66; p = 0.979;
p-interaction = 0.048). Accordingly, TCF7L2-PV was higher in non-obese subjects. Additionally,
we created obesity-specific GRS with ten T2D-polymorphisms and demonstrated for the first time
their higher strata-specific PV. In conclusion, we provide strong evidence supporting the need for
considering obesity when analyzing the TCF7L2 effects and propose the use of obesity-specific GRS
for T2D.
Keywords: TCF7L2; type-2 diabetes; obesity; T2D-genetic risk scores; TCF7L2-predictive value;
PREDIMED study
1. Introduction
It is common knowledge that obesity is associated with an increased risk of developing type
2 diabetes (T2D) [1–3]. However, current genetic information adds some heterogeneity to this
notion [4]. Thus, whereas some genetic variants may appear to be associated with T2D mainly
in obese subjects [5–7], others may show such association primarily in non-obese individuals [5,6,8].
Understanding these differences is crucial to improving the predictive value of genetic variants when
investigating T2D as well as gene–diet interactions. Currently, the rs7903146 C > T Single nucleotide
polymorphism (SNP) in the Transcription Factor 7-Like 2 (TCF7L2) gene is the locus most strongly
associated with T2D risk at the population level [9–11]. However, despite the strong overall association
of this SNP with higher T2D risk, various studies have suggested a modulation of this association by
obesity [6,12–15].
Cauchi et al. [6] first reported that the association between the TCF7L2-rs7903146 SNP and
prevalent T2D in Europeans was stronger in non-obese subjects. These findings were observed in other
populations [12–15]. Nevertheless, this potential heterogeneity by obesity has not been widely reflected
in the analytical approaches of subsequent investigations, and most of them have not formally tested
the interaction between the TCF7L2-rs7903146 polymorphism and obesity status in determining T2D
risk. A contributory factor is that previous findings were mainly based on cross-sectional or case-control
studies [5,6,9,12–14] with a strong likelihood of being affected by potential biases, more prospective
studies being required to assess this interaction on T2D incidence. Moreover, in addition to the
TCF7L-2-rs7903146 SNP, other SNPs have been associated with T2D risk [10,16–18]. These SNPs are
combined and analyzed together in the so-called genetic risk scores (GRS) to predict T2D [16–18].
However, simply summing up the number of risk alleles (unweighted or weighted) associated with
T2D obtained from non-stratified genome-wide association studies (GWAS) in conventional GRS
calculations may overlook important obesity-specific associations in T2D. Although the GRS usually
include dozens of SNPs associated with T2D, one of the most important SNPs is the rs7903146 C > T in
the TCF7L2 gene [9–11,16]. Recently, large prospective studies have focused on the interaction between
some multi-SNP GRS and BMI on T2D incidence [16–19], among them, that of Langerberg et al. [16],
employing a case-cohort design in the EPIC interact study. The authors found a statistically significant
interaction between a GRS comprising 49 SNPs associated with T2D and BMI (three categories) in
determining T2D incidence, the genetic risk being greater in lean subjects. However, on examining the
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interaction of each SNP of the GRS with BMI on T2D incidence, no statistically significant interaction
with BMI was found for the TCF7L2-rs7903146 SNP [16]. This could be because they did not specifically
test the interaction with obesity and made a strict correction for multiple comparisons due to the
simultaneous analyses of 7 phenotypes and 49 SNPs in the same study. Bearing the results of the
result in EPIC cohort in mind, this interaction, therefore, must be prospectively validated in studies
focusing on the TCF7L2-rs7903146 polymorphism (to avoid the need of correction for multiple SNP
comparisons) and obesity.
Furthermore, the heterogeneity of associations related to this locus also extends to BMI.
The T-allele, conferring higher T2D risk, has been associated with lower BMI in some studies [20–23],
but not in others [24–26]. A modulation of this association by T2D was first suggested by Helgason et
al. [27] who showed that the TCF7L2-T2D risk allele was correlated with decreased BMI in T2D cases
but not in controls. Similar results were observed both by Cauchi et al. [21] and in a meta-analysis
including more than 300,000 individuals [28], but further studies are required to explore this interaction
prospectively. Moreover, as previous findings come from studies focusing on either obesity or T2D, it is
necessary to obtain comprehensive evidence of the interplay between both interactions prospectively
in the same population. Therefore, our main aims were: (1) To investigate the interaction between
the TCF7L2-rs7903146 polymorphism and obesity status in determining T2D prevalence as well as
T2D incidence after a median ~6-year follow-up and (2) to examine whether the association of the
TCF7L2-rs7903146 SNP with obesity-related parameters depends on T2D status both at baseline and
prospectively in the PREvención con DIeta MEDiterránea (PREDIMED) study. In addition, a secondary
aim was to construct obesity-specific GRS (analyzing 10 T2D-SNPs previously characterized [16])
in determining T2D prevalence in a sub-sample of PREDIMED participants in order to extend the
findings to other T2D-SNPs.
2. Materials and Methods
The present study was conducted within the framework of the PREDIMED trial, the design of
which has been described in detail elsewhere [29]. Briefly, the PREDIMED study is a multicenter,
randomized, and controlled clinical trial aimed at assessing the effects of the Mediterranean
diet (MedDiet) on the primary cardiovascular prevention [30]. This study was registered at
controlled-trials.com (http://www.controlledtrials.com/ISRCTN35739639). Here we included 7018
participants from whom DNA was isolated, the TCF7L2-rs7903146 determined, and who had valid
data for the main clinical and lifestyle variables analyzed. From October 2003 physicians in Primary
Care Centers selected high cardiovascular risk participants. Eligible were community-dwelling persons
(55–80 years for men; 60–80 years for women) who met at least one of two criteria: T2D or three or
more cardiovascular risk factors [29]. The Institutional Review Board of each participating center
approved the study protocol, and all participants provided written informed consent. The trial was
stopped following the statistical analysis of data obtained up to December 2010 (median follow-up of
4.8 years), due to early evidence of the benefit of the MedDiet on the prevention of major cardiovascular
events [30]. However, the ascertainment of endpoints was extended. The present study is based on the
extended follow-up (until 30 June 2012) using the same methods to obtain updated information on
clinical events, including T2D. The median follow-up time in this extended follow-up was 5.7 years
(maximum: 8.7 years). The present study was mainly conducted as an observational prospective
cohort design with adjustment for the nutritional intervention in the longitudinal analyses. In addition,
some association analyses were carried out at baseline.
2.1. Demographic, Clinical, Anthropometric, and Dietary Measurements
The baseline examination included assessment of standard cardiovascular risk factors, medication
use, socio-demographic factors, and lifestyle variables by validated questionnaires [29,30]. Weight and
height were measured with calibrated scales and a wall-mounted stadiometer, respectively. BMI and
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the waist-to-height ratio were calculated. Obesity was defined as BMI ≥30 kg/m2. Percentage of body
fat was evaluated by using a validated equation [31].
2.2. Biochemical Determinations, DNA Extraction and Genotyping
At baseline, blood samples were obtained after overnight fasting. Fasting glucose and lipids
were measured as previously described [30,32]. Genomic DNA was extracted from buffy-coat and
the TCF7L2-rs7903146, was genotyped in the whole cohort on a 7900 HT Sequence Detection System
(Applied Biosystems, Foster City, CA, USA) using a fluorescent allelic discrimination TaqManTM
assay as previously reported [33]. Genotype frequencies did not deviate from Hardy–Weinberg
equilibrium expectations.
For the secondary outcome focused on the predictive value of the obesity-specific GRSs,
in addition to the TCF7L2-rs7903146 SNP, nine previously described SNPs associated with T2D,
and included in a 49-SNP T2D-GRS [16], were selected and genotyped. The selected SNPs were:
PRC1 (Protein Regulator of Cytokinesis 1)-rs12899811, ZFAND6 (Zinc Finger AN1-Type Containing
6)-rs11634397, CDC123_CAMK1D (Cell Division Cycle Protein 123 Homolog_Calcium/Calmodulin
Dependent Protein Kinase ID)-rs11257655, KCNQ1 (Potassium Voltage-Gated Channel Subfamily Q
Member 1)-rs163184, ADYC5 (adenylyl cyclase 6)-rs6798189, IGF2BP2 (Insulin Like Growth Factor
2 MRNA Binding Protein 2)-rs4402960, SLC30A8 (Solute Carrier Family 30 Member 8)-rs3802177,
KLHDC5 (Kelch Domain-Containing Protein 5)-rs10842994, and HMGA2 (High Mobility Group
AT-Hook 2)-rs2261181. Genotyping was carried out with the HumanOmniExpress Illumina array in a
sub-sample (all the participants from one of the PREDIMED field centers, the PREDIMED-Valencia
center; n = 1055 subjects), as it was not possible to genotype the whole cohort. Genotype frequencies
did not deviate from Hardy–Weinberg equilibrium expectations.
2.3. Outcomes and Follow-Up
Clinical diagnosis of T2D was an inclusion criterion of the PREDIMED study [29], and these
subjects were considered as prevalent cases of T2D. Incidence of T2D was a pre-specified secondary
outcome of the PREDIMED trial [30]. New-onset diabetes during follow-up was diagnosed using
the American Diabetes Association criteria, namely fasting plasma glucose levels ≥7.0 mmol/L
(≥126.1 mg/dL) or 2-h plasma glucose levels ≥11.1 mmol/L (≥200.0 mg/dL) after a 75-g oral glucose
load, as previously reported [32]. A review of all medical records of participants was completed yearly
in each center by physician-investigators who were blinded to the intervention. When new-onset
diabetes cases were identified on the basis of a medical diagnosis reported in the medical charts or on
a glucose test during routine biochemical analyses (conducted at least once per year), these reports
were sent to the PREDIMED Clinical Events Committee [32]. When a new case of T2D was detected,
the glucose analysis was repeated within the next three months, so that the new case of diabetes could
be confirmed by the adjudication committee. Cases that occurred between 1 October 2003 and 30 June
2012 (maximum: 8.7 years; median: 5.7 years) were included in the present analysis (n = 312).
Given that the study involved an open cohort, in which the inclusion of participants lasted from
1 October 2003 to 1 December 2009, not all participants had the same length of follow-up period [29].
Hence for the longitudinal analyses of BMI in relation to the polymorphism and T2D, two follow-up
periods were selected; one of up to four years and the other up to six years. There were a greater
number of participants in the first period (n = 3141), as most of the cohort completed this follow-up
period. A lower number of participants had anthropometric measurements at six years (n = 1750),
but this group was considered to be of interest both for the internal replication of the finding and for
providing more evidence of the interaction. Only participants whose anthropometric data had been
directly measured were included.
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2.4. Statistical Analyses
The present analysis was mainly conducted as an observational prospective cohort study with
adjustment for the nutritional intervention in longitudinal analyses. In addition, some analyses were
carried out cross-sectionally at baseline (n = 7018). Prevalence of diagnosed T2D was analyzed as
the dependent variable at baseline. In the longitudinal analysis, incidence of T2D was considered as
the end-point in non-diabetic subjects (n = 3607). Moreover, baseline and annual BMI evolution was
considered as the dependent variable for evaluating the interaction of the polymorphism with T2D in
determining BMI.
2.4.1. Baseline Association and Interaction Analyses in Determining T2D Prevalence and
Obesity-Related Variables
Chi-square tests were used to test differences in percentages. We first tested the polymorphism
by considering the 3 genotypes. The interactions between the TCF7L2-rs7903146 polymorphism and
obesity in determining T2D prevalence at baseline was tested by multivariable logistic regression
models including main effect and interaction terms. Models were adjusted for basic potential
confounders (age, gender, and center) (Model 1). Afterwards, an additional control for more potential
confounders such as alcohol consumption, physical activity, adherence to the MedDiet, total energy
intake, hypertension, and dyslipidemias was undertaken (Model 2). Analyses stratified by obesity
status were also undertaken for models 1 and 2. CC subjects were considered as the reference category
and the effect in CT and TT was estimated. Odds ratios (OR) and 95% Confidence intervals (CI) were
estimated. Likewise, the interaction between the TCF7L2 polymorphism and T2D in determining
obesity prevalence at baseline was evaluated by multivariable logistic regression models (model 1
and model 2), and stratified analysis by T2D status undertaken. In addition, associations between
the TCF7L2 polymorphism and baseline BMI and other obesity-related variables were analyzed by
linear regression models including main effects and interaction terms. Multivariable adjustments for
potential confounding variables were carried out as indicated above. Analyses stratified by T2D were
also undertaken.
2.4.2. Interaction Analysis between the TCF7L2-rs7903146 Polymorphism and Obesity in Determining
T2D Incidence
This analysis was carried out in non-T2D subjects at baseline. We used Cox regression models
with the length of follow-up as the primary time variable. Follow-up time was calculated from the
date of enrollment to the date of diagnosis of T2D for cases, and to the date of the last visit or the
end of the follow-up period (30 June 2012 for non-cases), or the date at death, whichever came first.
Hazard ratios (HR) with 95% CI for the TCF7L2-rs7903146 genotypes (three categories), stratified by
obesity were computed. Afterwards, C-allele carriers were grouped together and compared with
C-carriers (recessive model). Multivariable Cox regression models with main effects and interaction
terms were computed. In multivariable Model 1 (basic model) we adjusted for sex, age, center,
and intervention group. In multivariable Model 2 additional adjustments were undertaken as
previously described. Stratified analyses by obesity were carried out. In addition, Kaplan–Meier
survival curves (one minus the cumulative T2D free survival) were plotted to estimate the probability
of remaining free of T2D during follow-up depending on the TCF7L2 genotype and obesity status.
2.4.3. Predictive Value Calculations for the TCF72-rs7903146 Polymorphism on T2D Incidence and
Prevalence in the Whole PREDIMED Participants
To estimate the predictive ability of the genetic models depending on the obesity status, we used
two approaches: (a) In non-T2D subjects, we estimated its sensitivity, specificity, positive predictive
value (PPV), negative predictive value (NPV) for two categories (recessive model) in predicting T2D
incidence taking into account obesity status; (b) At baseline, we estimated the area under the receiver
operating characteristic curve (AUC) [19] of the TCF7L2-rs7903146 (as 0, 1 and 2) to predict T2D
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prevalence depending on obesity status (we selected the recessive and additive models for T2D
incidence and prevalence prediction based on the observed association results).
2.4.4. Construction of Obesity-Specific GRS with the TCF7L2 and Other T2D-SNPs; Association and
Evaluation of the PV for T2D Prevalence
Taking into account the obesity-specific association of the TCF7L2 polymorphism with T2D,
our secondary aim was to extend this analysis to more T2D SNPs. This was considered a pilot
study as we only have genotype data from one of the PREDIMED field centers (PREDIMED-Valencia
participants with complete data; n = 1000 participants; 46% T2D prevalence). These SNPs were
selected from the list of 49 SNPs associated with T2D that were used in the EPIC-InterAct study
for the multi-SNP GRS construction and T2D association [16]. From the list of the 49 T2D-SNP,
in addition to the TCF7L2-SNP, we selected those included in our genotyping array (n = 27) and
specifically tested the association between the corresponding SNP and T2D by obesity status. Those
SNPs showing suggestive heterogeneity in the associations in our population were included in the
obesity-specific GRS analyses (PRC1-rs12899811, ZFAND6-rs11634397, CDC123_CAMK1D-rs11257655,
KCNQ1-rs163184, ADYC5-rs6798189, IGF2BP2-rs4402960, SLC30A8-rs3802177, KLHDC5-rs10842994,
and HMGA2-rs2261181). For some of these SNPs (in the ZFAND6, ADYC5, IGF2BP2, SLC30A8,
KLHDC5, and HMGA2 genes), statistically significant or borderline significant interactions with
BMI (or with waist circumference) in determining T2D were reported in the EPIC-InterAct study
(p = 0.055, p < 0.01; p = 0.034; p = 0.099; p = 0.10, respectively) [16]. However, the authors did not
construct obesity-specific GRS. Depending on the results obtained in the stratified analysis, SNPs were
grouped in two obesity-specific GRS. One GRS included five T2D-SNPs more associated with T2D
in obese subjects (obGRS); and the other GRS included five T2D-SNPs more associated with T2D in
non-obese subjects (nobGRS). nobGRS: TCF7L2-rs7903146, PRC1-rs12899811, ZFAND6-rs11634397,
CDC123_CAMK1D-rs11257655 and KCNQ1-rs163184; obGRS: ADYC5-rs6798189, IGF2BP2-rs4402960,
SLC30A8-rs3802177, KLHDC5-rs10842994 and HMGA2-rs2261181. SNPs in these GRS were considered
as additive (0, 1, or 2 risk alleles). Multivariable logistic regression models with prevalent T2D as
dependent variable and the obesity-specific GRS (as continuous) as independent variables, adjusted for
age, sex, and obesity were fitted for the total and for obese and non-obese subjects; OR and 95% CI
were calculated to estimate the association between the GRS and T2D.
Finally; the AUC of the two GRS predicting T2D at baseline in the PREDIMED-Valencia subsample
by obesity status (obesity-specific GRS) in the whole population and in obese and non-obese subjects
were calculated.
2.4.5. Longitudinal Association and Interaction Analysis between the TCF7L2-rs7903146
Polymorphism and T2D in Determining BMI
The longitudinal influence of the TCF7L2-rs7903146 polymorphism and T2D on BMI was analyzed
by multivariable-ANCOVA of repeated measures including those subjects having complete data
at baseline, 1, 2, 3, and 4 years (first four-year period) and at baseline, 1, 2, 3, 4, 5, and 6 years
(second six-year period).
2.4.6. Power Calculations
Sample size in the PREDIMED study (n = 7447 participants) was estimated taking into account
the expected incidence of the primary outcome (incidence of cardiovascular diseases) and the
differences in the effects of the dietary interventions to be detected among groups [30]. In the
present study, we focused on T2D prevalence and T2D incidence in PREDIMED participants with
the TCF7L2-rs7903146 data available (n = 7018). At baseline our study (including n = 3607 non-T2D
and n = 3411 T2D subjects), had a large statistical power (>80%) to detect associations (OR >1.2) at
alpha = 5% between the TCF7L2 polymorphism and T2D prevalence in obese and non-obese subjects.
Taking into account the similar sample size of T2D and non-T2D subjects at baseline, as well as the %
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of obese and non-obese subjects, our study has the strong advantage of having comparable statistical
power to detect a similar association in both groups. Therefore, the lack of association between the
TCF7L2-rs7903146 polymorphism and T2D risk in the stratified analyses in obese or non-obese subjects
is not due to the lack of power in one of the groups. At baseline, our sample size was adequately
powered (power >80%) to detect statistically significant TCF7L2-obesity interactions (at alpha <5%) in
determining T2D prevalence (>40%) at an interaction effect of OR for interaction >1.21 (co-dominant
model). Similar estimations in sample size and effects were computed for the interaction between the
TC7L2 polymorphism and T2D in determining obesity risk. For continuous variables our sample size
at baseline was adequately powered (power >80%) to detect statistically significant interactions and
associations in the effect strata. In the longitudinal analysis, taking into account that the number of
incident cases of T2D was small (n = 312) and that only non-T2D subjects at baseline were considered
(n = 3607), the power to detect statistically significant interactions and association was lower than
in the baseline analysis. Therefore, at alpha = 5% and beta = 20%, our sample size was adequately
powered (>80%) to detected interaction effects (recessive model) of HR >1.75. Statistical analyses were
performed with the IBM SPSS Statistics version 22, NY. All tests were two-tailed and p values < 0.05
were considered statistically significant.
3. Results
Table 1 shows the characteristics of the studied population (n = 7018 subjects) as a whole and
depending on the T2D status at baseline.
Table 1. Demographic, clinical, lifestyle, and genetic characteristics of the study participants at baseline
according to the diabetes status.
Total (n = 7018) Non-Diabetic Subjects (n = 3607) T2D Subjects (n = 3411) p
Age (years) 67.0 ±6.2 66.6 ±6.1 67.4 ±6.3 <0.001
Weight (Kg) 76.8 ±11.9 76.7 ±11.7 76.9 ±12.2 0.476
BMI (Kg/m2) 30.0 ±3.8 30.1 ±3.7 29.9 ±4.0 0.042
Waist circumference (cm) 100.4 ±10.6 99.7 ±10.6 101.2 ±10.5 <0.001
Body fat (%) 39.3 ±7.4 39.9 ±7.2 38.7 ±7.7 <0.001
Female sex: n, % 4025 (57.4) 2232 (61.9) 1793 (52.6) <0.001
Current smokers: n, % 989 (14.1) 581 (16.1) 408 (12.0) <0.001
TCF7L2-rs7903146: n, % <0.001
CC 2770 (39.5) 1612 (44.7) 1158 (33.9)
CT 3249 (46.3) 1569 (43.5) 1680 (49.3)
TT 999 (14.2) 426 (11.8) 573 (16.8)
Intervention groups: n, % 0.059
MedDiet + EVOO 2411 (34.4) 1204 (33.4) 1207 (35.4)
MedDiet + nuts 2316 (33.0) 1235 (34.2) 1081 (31.7)
Control group 2291 (32.6) 1168 (32.4) 1123 (32.9)
Energy intake (kcal/day) 2276 ±607 2322 ±603 2228 ±607 <0.001
Total fat (% energy) 39.2 ±6.8 38.5 ±6.5 39.9 ±7.0 <0.001
Saturated fat (% energy) 10.0 ±2.3 9.7 ±2.2 10.2 ±2.3 <0.001
MUFA (% energy) 19.5 ±4.6 19.2 ±4.3 19.7 ±4.8 <0.001
Carbohydrates (% energy) 41.9 ±7.2 42.8 ±6.9 40.9 ±7.3 <0.001
Adherence to the MedDiet 8.7 ±2.0 8.7 ±2.0 8.6 ±2.0 0.003
Alcohol consumption (g/day) 8.4 ±14.2 9.1 ±14.8 7.6 ±13.5 <0.001
Physical activity (MET.min/day) 231.6 ±240.4 225.5 ±226.8 238.0 ±253.8 0.030
SBP (mm·Hg) 149.3 ±20.8 149.0 ±20.6 149.7 ±21.0 0.187
DBP (mm·Hg) 83.4 ±11.0 84.5 ±11.0 82.2 ±10.9 <0.001
Total cholesterol (mg/dL) 211.0 ±39.4 220.0 ±39.8 201.4 ±36.6 <0.001
LDL-C (mg/dL) 130.3 ±35.1 137.9 ±36.2 122.1 ±31.8 <0.001
HDL-C (mg/dL) 53.8 ±14.1 55.8 ±14.6 51.7 ±13.2 <0.001
Triglycerides (mg/dL) 137.4 ±79.7 132.6 ±73.9 142.4 ±85.2 <0.001
Fasting glucose (mg/dL) 122.2 ±41.6 98.2 ±16.4 147.4 ±45.1 <0.001
Values are mean ± SD for continuous variables and number (%) for categorical variables. T2D indicates Type 2
diabetes. BMI indicates body mass index, MUFA, Monounsaturated fatty acids; MedDiet, Mediterranean diet;
EVOO, extra virgin olive oil, SPB: Systolic blood pressure, DBP: Diastolic blood pressure. p: p-value for the
comparisons (means or %) between non-diabetic and type 2 diabetic subjects.
Nutrients 2016, 8, 793 8 of 18
3.1. Interaction between the TCF7L2-rs7903146 Polymorphism and Obesity in Determining T2D at Baseline
Even though the TCF7L2-rs7903146 polymorphism was significantly associated with a higher T2D
prevalence in the whole population (p = 3.1 × 10−21), this association was of greater magnitude (OR:
2.26; 95% CI: 1.84–2.78 for TT compared to CC homozygotes; p = 1.6 × 10−14) in non-obese (n = 3739)
than in obese (n = 3279) subjects (OR: 1.51; 95% CI: 1.22–1.92 for TT compared to CC homozygotes;
p = 0.0002) even after multivariable adjustment (Table 2).
Table 2. Association between the TCF7L2-rs7903146 polymorphism and prevalence of T2D depending
on the obesity status at baseline. Stratified logistic regression analysis.
Non-Obese p 3 for Interaction Obese
n OR 95% CI p-Value Genotype× Obesity n OR 95% CI p-Value
Model 1 1
TCF7L2 0.002
CC 1424 1.00 (reference) 1346 1.00 (reference)
CT 1742 1.79 (1.55–2.08) 5.5 × 10−15 1507 1.28 (1.10–1.49) 0.0012
TT 573 2.32 (1.90–2.85) 5.4 × 10−16 426 1.51 (1.21–1.89) 0.0003
p 4: 2.5 × 10−20 p 4: 0.0002
Model 2 2
TCF7L2
CC 1.00 (reference) 1.00 (reference)
CT 1.78 (1.54–2.09) 1.4 × 10−14 0.003 1.27 (1.09–1.48) 0.0020
TT 2.26 (1.84–2.78) 1.6 × 10−14 1.53 (1.22–1.92) 0.0002
p 4: 4.3 × 10−19 p 4: 0.00017
1 Model 1: adjusted for sex, age, and field center; 2 Model 2: adjusted for sex, age, field center, total energy intake,
adherence to the Mediterranean diet, alcohol intake, smoking, physical activity, dyslipidemia, and hypertension;
3 p-value obtained for the interaction term between the TCF7L2 genotype and obesity in the corresponding
multivariable logistic regression model; 4 p-value obtained for the global TCF7L2 polymorphism in the
multivariable logistic regression model.
3.2. Interaction between the TCF7L2-rs7903146 Polymorphism and T2D in Determining Obesity-Related
Measures at Baseline
At baseline, the T2D risk allele was significantly associated with lower averages for BMI, body fat,
waist-to-height ratio, and lower prevalence of obesity (BMI ≥30 kg/m2) (Supplementary Materials
Table S1). However, we detected a strong heterogeneity in these associations depending on T2D
status. Figure 1 shows these interactive effects on BMI (A) and % body fat (B), the TCF7L2-rs7903146
polymorphism being inversely associated with these traits only in T2D subjects (p-interactions < 0.05).
Likewise, the inverse association between the TCF7L2-rs7903146 polymorphism and obesity at baseline
(Table 3) was statistically significant in T2D (p = 0.0002) but not in non-T2D subjects (p = 0.737).
Accordingly, the multivariable adjusted OR for obesity in TT subjects compared to CC individuals was
0.63; 95% CI 0.51–0.78; p = 1.63 × 10−5 in T2D, showing a reduced risk, and no association (0.93; 95%
CI: 0.74–1.16; p = 0.493) in non-diabetic subjects.
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Figure 1. Adjusted means of BMI (a) and % body fat (b) at baseline depending on the TCF7L2-rs7903146
polymorphism and T2D diabetes status (n = in 7018 PREDIMED participants at baseline. Means were
adjusted for age, sex, center, total energy intake, physical activity, smoking, drinking, adherence to
the Mediterra ean diet, dyslipidemia, and hypertension. The p-values for the interaction terms were
obtained in th corresponding multivariable adjusted models. p 1 and p 2 values were btained for the
multivari ble comparison of means etween depending on the T2D strata in non-dia etic (n = 3607)
subjects and T2D (n = 3411) subjects, respectively. Error bars: SE of means.
Table 3. Association between the TCF7L2-rs7903146 polymorphism and obesity depending on T2D
status. Stratified logistic regression analysis.
Non-Diabetic p 3 for Interaction T2D Subjects
n OR 95% CI p-Value Genotype× T2D n OR 95% CI p-Value
Model 1 1
TCF7L2 0.008
CC 1612 1.00 (reference) 1158 1.00 (reference)
CT 1569 1.05 (0.91–1.20) 0.544 1680 0.78 (0.67–0.91) 0.001
TT 426 0.96 (0.77–1.19) 0.694 573 0.64 (0.52–0.78) 2.0 × 10−5
p 4: 0.685 p 4: 3.90 × 10−5
Model 2 2
TCF7L2
CC 1.00 (reference) 1.00 (reference)
CT 1.05 (0.91–1.21) 0.529 0.014 0.77 (0.66–0.90) 0.001
TT 0.93 (0.74–1.16) 0.493 0.63 (0.51–0.78) 1.6 × 10−5
p 4: 0.528 p 4: 3.02 × 10−5
1 Model 1: adjusted for s x, age, and field center; 2 M del 2: adjusted for sex, ag , field center, total
energy intake, a herence to the Mediterranean diet, alcohol intake, smoking, physical activity, dyslipid mia,
and hypertension; 3 p-value obtained for the interaction term between the TCF7L2 genotype and type-2
diabetes in the corresponding multivariable logistic regression model; 4 p-value obtained for the global TCF7L2
polymorphism in the multivariable logistic regression model.
3.3. Interaction between the TCF7L2-rs7903146 Polymorphism and Obesity in the Incidence of T2D
We analyzed the interaction between the TCF7L2-rs7903146 polymorphism and obesity status in
determining the incidence of T2D in non-d abetic su ject (n = 3607) over the extended follow-u period
(with med an 5.7 years) (Table 4). We bserved that the association between the TCF7L2-rs7903146
and T2D incidence only was statistically significant in obese subjects (p = 0.035 in the basic model and
p = 0.045 in the additionally adjusted model). Thus, we observer a significantly stronger association in
non-obese (HR: 1.81; 95% CI: 1.13–2.92, p = 0.013 for TT versus CC) than in obese individuals (HR: 1.01;
95% CI: 0.61–1.66; p = 0.979); p-interaction = 0.048. A recessive effect was found in agreement with
results obtained in previous studies [20]. Figure 2 shows T2D-free survival Kaplan–Meier curves in
non-obese (A) and obese subjects (B). Taking into account that a recessive effect was noted, homozygous
subjects for the risk allele (TT) were also compared with C-allele carriers.
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Furthermore, we estimated the influence of obesity status on T2D incidence over the
5.7-year median follow-up period in this population in the whole sample and depending on the
TCF7L2-rs7903146 polymorphism. Although for the whole population of T2D-free subjects at baseline
obesity was significantly associated with higher TD2 risk (HR: 1.44; 95% CI: 1.14–1.82; p = 0.002),
this association was heterogeneous in the different genotypes (Supplementary Materials Figure S1).
Thus, in CC subjects, obesity was strongly associated with T2D incidence (HR: 1.75; 95% CI: 1.22–2.51;
p = 0.002 in obese compared with non-obese). This significant association decreased in CT subjects
(HR: 1.45; 95% CI: 102–2.07; p = 0.041 in obese versus non-obese subjects). No significant association
between obesity status and T2D incidence was found in subjects with the TT genotype (HR: 0.79; 95%
CI: 0.43–1.46; p = 0.454).
Table 4. Incidence and hazard ratios (HR) for T2D depending on the TCF7L2-rs7903146 polymorphism
and stratified by obesity after 5.7 years of median follow-up.
Obese Subjects 1 (n = 1693)
Cases Non-Cases Person-Years Incidence
Rate 4
Model 1 2 Model 2 3
HR 95% CI p-Value HR 95% CI p-Value
TCF7L2
genotypes 0.960 0.965
CC 73 677 4117.5 17.7 1.00 (reference) 1.00 (reference)
CT 79 669 4203.8 18.8 1.04 (0.76–1.44) 0.777 1.05 (0.76–1.46) 0.750
TT 21 174 1094.0 19.2 1.01 (0.62–1.65) 0.957 1.01 (0.61–1.66) 0.979
Non-Obese Subjects (n = 1904)
Model 1 2 Model 2 3
TCF7L2
genotypes 0.035 0.045
CC 56 803 4819.0 11.6 1.00 (reference) 1.00 (reference)
CT 57 758 4661.8 12.2 1.08 (0.75–1.57) 0.671 1.14 (0.79–1.66) 0.531
TT 26 204 1285.7 20.2 1.82 (1.14–2.92) 0.012 1.81 (1.13–2.92) 0.013
1 Obesity: BMI ≥30 kg/m2; 2 Model 1: Adjusted for sex, age, field center, and dietary intervention group;
3 Model 2: Adjusted for variables in model 1 plus total energy intake, adherence to the Mediterranean diet,
alcohol intake, smoking, physical activity, dyslipidemia, and hypertension at baseline; 4 Crude incidence rates
are expressed per 1000 person-years of follow-up.
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Figure 2. One minus the cumulative T2D-free survival by TCF7L2-rs7903146 genotypes in non-diabetic
subjects at baseline (n = 3607) depending of the obesity status: non-obese subjects (a) and obese
subjects (b). Cox regression models with outcome of T2D incidence by the TCF7L2-rs7903146
polymorphism (CC, CT and TT) were adjusted for sex, age, center, intervention group, alcohol, smoking,
total energy intake and adherence to the Mediterranean diet, physical activity, smoking, drinking,
dyslipidemia, and hypertension at baseline. HR and 95% CI were obtained in the multivariable adjusted
model. The p-values for the TCF7L2 polymorphism and for the corresponding genotypes (TT versus
CC or TT versus C-carriers) were obtained in the multivariable adjusted models.
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3.4. Predictive Ability of the TCF7L2-rs7903146 on T2D Incidence and Prevalence Depending on
Obesity Status
Supplementary Materials Table S2 shows the sensitivity, specificity, PPV, and NPV for the
TCF7L2-SNP (as recessive according to the observed association effect) on predicting T2D incidence in
non-TD2 PREDIMED participants. Significantly better parameters were obtained in non-obese subjects
(p = 0.03) than in obese subjects (p = 0.787).
Likewise, in the ROC analysis, the AUC for the TCF7L2 SNP (additive model) for T2D prevalence
in PREDIMED participants was higher in non-obese (AUC: 0.58; p = 1.37 × 10−17) than in obese
subjects (AUC: 0.53; p = 1.4 × 10−4) (Supplementary Materials Figure S2).
3.5. Obesity Specific-GRS Construction, Association with T2D Prevalence and Estimations of the Predictive
Value of These GRS in a Subsample of Participants
Our secondary aim was to extend the TCF7L2 analysis to more T2D SNPs. This was
considered a pilot study as we only have genotype data from one of the PREDIMED field
centers (n = 1000 PREDIMED-Valencia participants with complete data). In addition to the
TCF7L2-rs7903146 SNP, we selected nine T2D-SNPs from the list of the 49 SNPs included in
the T2D-GRS used in the EPIC-Interact Study [16] (see statistical analysis for the SNP selection)
and tested their association with T2D prevalence by obesity strata in our sample. Those SNPs
showing significant (or near significance) associations in one of the obesity strata were selected
for combination in the corresponding obesity-specific GRS (nobGRS and obGRS). Five SNPs in
each score were combined (nobGRS: TCF7L2-rs7903146, PRC1-rs12899811, ZFAND6-rs11634397,
CDC123_CAMK1D-rs11257655 and KCNQ1-rs163184; obGRS: ADYC5-rs6798189, IGF2BP2-rs4402960,
SLC30A8-rs3802177, KLHDC5-rs10842994, and HMGA2-rs2261181 as indicated in methods).
Supplementary Materials Figure S3 shows frequency distribution of nobGRS (A) and obGRS (B)
in the whole sample (n = 1000). First, we tested the association of these obesity-specific GRS with
T2D prevalence in obese and non-obese subjects (Supplementary Materials Table S3). As expected,
the nobGRS was significantly associated with T2D in non-obese subjects (p = 0.006). No significant
association was found for the nobGRS in obese subjects (p = 0.535). Likewise, the obGRS was
significantly associated with T2D in obese subjects (p < 0.001), and not associated in non-obese
subjects (p = 0.130). We also estimated the predictive value for these obesity-specific GRS for T2D in
the whole sample (Supplementary Materials Figure S4) and by obesity strata (Figure 3). When we
consider the obesity-specific GRS in their specific strata, we observed that the nobGRS had greater and
significantly AUC in non-obese (AUC: 0.581; p = 0.002) than in obese subjects (AUC: 0.522; p = 0.384).
Likewise, the obGRS had higher AUC in obese (0.591; p = 0.004) than in non-obese subjects (0.531;
p = 0.239), thus supporting our hypothesis.
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PREDIMED‐Valencia participants with complete data).  In addition  to  the TCF7L2‐rs7903146 SNP, 
we  selected  nine  T2D‐SNPs  from  the  list  of  the  49  SNPs  included  in  the  T2D‐GRS  used  in  the 
EPIC‐Interact Study [16] (see statistical analysi  for the SNP selection) and tested their association 
with  T2D  prevale ce  by  besity  strata  in  our  sample. Those  SNPs  showing  significant  (or  near 
significance)  associations  in  one  of  the  obesity  strata  were  selected  for  combination  in  the 
corresponding obesity‐specific GRS (nobGRS and obGRS). Five SNPs in each score were combined 
(nobGRS:  TCF7L2‐rs7903146,  PRC1‐rs12899811,  ZFAND6‐rs11634397, 
CDC123_CAMK1D‐rs11257655  and  KCNQ1‐rs163184;  obGRS:  ADYC5‐rs6798189, 
IGF2BP2‐rs4402960, SLC30A8‐rs3802177, KLHDC5‐rs10842994, a d HMGA2‐rs2261181 as indicated 
in methods). Supplementary Materials Figure S3 shows frequency distribution of nobGRS ( ) and 
obGRS (B) in the whole sample (n = 1000). First, we tested the association of these obesity‐specific 
GRS with T2D prevalence in obese and non‐obese subjects (Supplementary Materials Table S3). As 
expected, the nobGRS was significantly associated with T2D  in non‐obese subjects  (p = 0.006). No 
significant association was found for the nobGRS in obese subjects (p = 0.535). Likewise, the obGRS 
was significantly associated with T2D in obese subjects (p < 0.001), and not associated in non‐obese 
subjects (p = 0.130). We also estimated the predictive value for these obesity‐specific GRS for T2D in 
the whole sample (Supplementary Materials Figure S4) and by obesity strata (Figure 3). When we 
consider the obesity‐specific GRS in their specific strata, we observed that the nobGRS had greater 
and significantly AUC in non‐obese (AUC: 0.581; p = 0.002) than in obese subjects (AUC: 0.522; p = 
0.384). Likewise, the obGRS had higher AUC in obese (0.591; p = 0.004) than in non‐obese subjects 
(0.531; p = 0.239), thus supporting our hypothesis. 
(a)  (b)
Figure 3. Cont.
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(a)  (b)
Figure 3. Receiver operating curves (ROC) of the two Genetic Risk Scores (GRS) [One
including T2D-SNPs more associated in obese subjects (obGRS); and the other including T2D-SNPs
more associated in non-obese subjects (nobGRS)] to predict T2D (prevalent) at baselin in the
PREDIMED-Valencia participant (n = 1000): (a) GRS in non-obese subjects; (b) nobGRS
in obese subjects; (c) obGRS in non-obese subjects; (d) obGRS in obese subjects. Areas under
the curves (AUC) and p-values are indicated. The straight line represents the ROC expected
by chance only. n = 493 non-obese and n = 507 obese with genotype data for all the SNPs
included in the GRS were analyzed. Five SNPs were included in each unweighted additive
(risk allele) GRS as follows: nob RS: TCF7L2-rs7903146, PRC1-rs12899811, ZFAND6-rs11634397,
CDC123-CAMK1D-rs11257655 and KCNQ1-rs163184; obGRS: ADYC5-rs6798189, IGF2BP2-rs4402960,
SLC30A8-rs3802177, KLHDC5-rs10842994, and HMGA2-rs2261181.
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Figure 4. Longitudinal effect of the TCF7L2-rs7903146 polymorphism on BMI over a 4-year follow-up
period in n = 3141 subjects depending on T2D status: (a) non-diabetic; (b) T2D subjects. Adjusted
means BMI depending on the polymorphism (co-dominant model) and T2D at baseline and 1, 2, 3 and
4 years of follow-up in all subjects having data for all the five measurements were estimated from a
repeated-measures ANOVA model with interaction terms adjusted for dietary intervention (MedDiet
versus control), sex, age, center, BMI, adherence to the Mediterranean diet (AdMedDiet), smoking,
drinking, and physical activity at baseline. Adjusted p values for the overall effect of the polymorphism
and for the interaction among the polymorphism and T2D, were obtained in the multivariable model.
3.6. Longitudinal Interaction between the TCF7L2-rs7903146 Polymorphism and T2D in BMI
At baseline, we have observed a shared interactive effect between the FCF7L2-rs7903146
polymorphism and T2D in determining BMI. Here we tested whether this shared interactive effect is
also observed longitudinally. We analyzed two periods based on the inclusion of a larger number of
participants (at four-year follow-up, with 3141 participants) or on a longer follow-up period (at six-year
follow-up, with 1750 participants). Figure 4 shows the association between the TCF7L2-SNP and
BMI longitudinally for every year of the four-year follow-up period. We observed a significant
Nutrients 2016, 8, 793 13 of 18
heterogeneity (p-interaction: 0.041) in non-diabetic (A) and in T2D (B) subjects. In T2D subjects the
association between the SNP and lower BMI was detected yearly (p-for the average inter-subjects
effects: 0.02), whereas in non-diabetic subjects no significant association with BMI was observed over
the follow-up period (p: 0.975). The later analysis, including participants with six years of follow-up,
confirmed these results (Supplementary Materials Figure S5).
4. Discussion
Combining longitudinal and cross-sectional analyses in a well-characterized population [30],
we have obtained new epidemiological evidence to unravel the complex relationship between the
TCF7L2-rs7903146 polymorphism, obesity, and T2D. At the population level, we have obtained
consistent results showing that, on the one hand, the TCF7L2-rs7903146 polymorphism significantly
interacts with obesity to determine the prevalence and incidence of T2D, and, on the other, that
T2D interacts with the TCF7L2-rs7903146 in BMI both at baseline and prospectively. As these three
variables are so closely interrelated [1,2] it is very difficult to distinguish cause from effect. According
to previous investigations [5,6,8], it seems most plausible that obesity status interacts with the TCF7L2
gene, prompting the TT risk genotype to associate itself with a higher incidence of T2D in lean subjects;
perhaps the effect we observed of the T-allele being associated with lower obesity risk in T2D subjects
is a secondary observation to the primary one. However, we cannot discard the real influence of the
T-allele on body weight. Despite this SNP being one of the strongest common genetic determinant of
T2D yet described [9–11,34], there is still much controversy over the molecular mechanisms involved
in how this genetic variation of TCF7L2 gene leads to altered biological function [35–38].
Although some previous studies [5,6,12–14] have described that the TCF7L2-rs7903146
polymorphism was more strongly associated with T2D in non-obese subjects, most of these studies
have been retrospective and prone to potential bias. Only one study has prospectively and
specifically analyzed the interaction between the TCF7L2-rs7903146 SNP and BMI in determining
T2D incidence [15]. However, this study included only men. Thus, our study, including both men
and women, is the first prospective report showing that at the population level (analyzing both
men and women) the TCF7L2 polymorphism is more associated with T2D incidence in non-obese
subjects. Our results support and extend the findings, adding more prospective evidence to the
heterogeneity in the association. Recent prospective studies [16–19] have analyzed the interaction
between genetic variants and BMI on T2D using multi-SNP GRS [39] rather than focusing specifically
on the TCF7L2-SNP (which was only one of the loci in the GRS). In the EPIC-InterAct study [16],
where they analyzed the interaction between each of the SNPs of the GRS and BMI on T2D, despite the
fact that they found that the global GRS significantly interacted with BMI, these authors did not find
any significant interaction of BMI with the TCF7L2 SNP after correction for multiple comparisons.
These results may be due to the fact that they undertook multiple comparisons and the statistical
significance was set at p < 0.05/343. These results could be considered as a false negative and so clearly
show the need to continue investigating this interaction in more depth. Several studies have examined
the effect of other T2D-SNPs integrated in GRSs, among them that from Talmud et al. [19], including
seven prospective studies and using a T2D 65-SNP GRS. They showed heterogeneity on the effects of
the GRS by BMI in determining T2D (the 65-SNP GRS being associated with higher T2D incidence
in leaner individuals). Talmud et al. [19] also evaluated the predictive value of the GRS and showed
heterogeneity by BMI [19]. In our study, we have found better results for the TCF7L2-rs7903146 in
predicting T2D in non-obese than in obese subjects. In addition to the TCF7L2, other genes [8,40,41]
could be associated with higher T2D risk in non-obese individuals. Moreover a recent study carried out
in Chinese subjects [42] investigated the association between a 25-SNP GRS (global and by SNP) and
T2D prevalence in obese and non-obese subjects separately, concluding that some SNP were strongly
associated with T2D in non-obese subjects, whereas others were specific for obese subjects. However,
the authors did not construct obesity-specific GRS.
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An important finding of our study is that, unlike previous studies, we have constructed
obesity-specific GRS by combining in the specific score only those SNPs more associated with T2D in the
specific obesity strata. Thus we constructed an obGRS (including the T2D-SNPs more associated with
T2D in obese subjects) and a nobGRS (including the T2D-SNPs more associated with T2D in non-obese
subjects, such as the TCF7L2). As far as we know, this is the first time that the use of obesity-specific GRS
has been tested. Our results show that, consistent with our hypothesis, a GRS including the TCF7L2
polymorphism and others in a nobGRS present greater AUC for T2D prevalence in non-obese than in
obese subjects. Likewise, the obGRS presented greater AUC for T2D in obese subjects. These results
support the desirability of taking stratification by obesity into account on analyzing the genetic
influence in T2D. One limitation of our results is that we only have tested these GRS in a subsample
of the PREDIMED study (all the subjects in a field center with genetic data available). Additional
replication in the whole cohort or in another population, also using T2D incidence, will be needed to
establish the concept of obesity-specific GRS. However, our preliminary results are important for this
upcoming work and will improve the predictive values of the obesity-specific GRS. Thus, whereas two
SNPs may present similar overall significant association with T2D incidence, this significance could be
driven in one case by obesity and in the other by leanness, making it inappropriate to combine them in
the same GRS.
Moreover, our results will be highly relevant for future nutrigenetic studies, taking into account
that currently heterogeneity by obesity is not evaluated when analyzing gene–diet interactions in
determining T2D risk. Controversial results have been reported regarding the protective effects of
fiber intake depending on the TCF7L2 polymorphism [43]. According to our results, in studies aimed
at analyzing gene–diet interactions involving the TCF7L2 polymorphism in the determination of
T2D, stratification by obesity status should be needed. Likewise, much more investigation regarding
gene–diet interactions in lean subjects with the high-risk TCF7L2-rs7903146-genotype is needed to
better characterize the potential dietary modulations for T2D prevention.
Overall, these data support the need to carry out analyses stratified by obesity when evaluating
genetic associations and gene–diet interactions in determining T2D. This will be key when examining
the sensitivity and specificity of genetic analyses to predict T2D risk, as these parameters may vary
substantially depending on the obesity status of the person submitted to the test. Along these lines,
some studies examining the potential utility of the TCF7L2 gene variant for the prediction of T2D
have produced disappointing results [44,45]. Assessing heterogeneity by obesity and other factors
may help to fill the gap that exists between genetic discoveries and their practical applications to T2D
prevention [46,47].
In terms of obesity as an outcome, our results also suggest an inverse association of the TCF7L2
polymorphism with BMI in T2D subjects. In agreement with us, a meta-analysis of GWAs [28] detected
such heterogeneity at the cross-sectional level but did not explore this association longitudinally,
with stronger effects in T2D case/control studies (the T2D-risk allele associated with lower BMI) than
in population-based studies. As far as we know, our study is the first to show a prospective interaction
between the TCF7L2-rs7903146 polymorphism and T2D in determining BMI (up to six years). This is
also important as other studies have focused on gene–diet interactions on weight changes involving
the TCF7L2 polymorphism [48]. In these studies stratification by T2D status should be considered to
reduce the confounding effect of this heterogeneity. Our interaction results will be highly relevant for
upcoming nutrigenetic studies focusing on the influence of the TCF7L2 polymorphism on BMI.
5. Conclusions
In conclusion, we have comprehensively demonstrated that the TCF7L2-rs7903146 polymorphism
interacts with obesity status in determining T2D risk, emphasizing the heterogeneity of genetic variants’
T2D risk prediction. We support stratified analysis by obesity or by T2D, depending on whether the
association of the TCF7L2 polymorphism with T2D or with BMI is being investigated. We suggest
that taking into account this heterogeneity by obesity will improve the predictive value of this SNP in
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determining T2D risk. Moreover, this heterogeneity of the TCF7L2-rs7903146 effects on T2D can be
extended to other T2D SNPs and we have created for the first time the concept of obesity-specific GRS.
We have tested two obesity-specific GRS, showing an increase in the predictive value of the GRS in
the corresponding strata. The creation and validation of the proposed obesity-specific GRS, including
more SNPs, will be important in the new era of personalized genetic risk prediction for T2D as well as
in nutrigenetic studies for more accurate testing of gene–diet interactions.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/8/12/793/s1.
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